

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk



Yaohua Yang¹, Lang Wu¹, Xiang Shu¹, Yingchang Lu¹, Xiao-Ou Shu¹, Qiuyin Cai¹, Alicia Beeghly-Fadiel¹, Bingshan Li², Fei Ye³, Andrew Berchuck⁴, Hoda Anton-Culver⁵, Susana Banerjee⁶, Javier Benitez^{7,8}, Line Bjørge^{9,10}, James D. Brenton¹¹, Ralf Butzow¹², Ian G. Campbell^{13,14}, Jenny Chang-Claude^{15,16}, Kexin Chen¹⁷, Linda S. Cook^{18,19}, Daniel W. Cramer^{20,21}, Anna deFazio^{22,23}, Joe Dennis²⁴, Jennifer A. Doherty²⁵, Thilo Dörk²⁶, Diana M. Eccles²⁷, Digna Velez Edwards²⁸, Peter A. Fasching^{29,30}, Renée T. Fortner¹⁵, Simon A. Gayther³¹, Graham G. Giles^{32,33,34}, Rosalind M. Glasspool³⁵, Ellen L. Goode³⁶, Marc T. Goodman³⁷, Jacek Gronwald³⁸, Holly R. Harris^{39,40}, Florian Heitz^{41,42}, Michelle A. Hildebrandt⁴³, Estrid Høgdall^{44,45}, Claus K. Høgdall⁴⁶, David G. Huntsman^{47,48,49,50}, Siddhartha P. Kar²⁴, Beth Y. Karlan⁵¹, Linda E. Kelemen⁵², Lambertus A. Kiemeny⁵³, Susanne K. Kjaer^{44,54}, Anita Koushik⁵⁵, Diether Lambrechts⁵⁶, Nhu D. Le⁵⁷, Douglas A. Levine^{58,59}, Leon F. Massuger⁶⁰, Keitaro Matsuo^{61,62}, Taymaa May⁶³, Iain A. McNeish^{64,65}, Usha Menon⁶⁶, Francesmary Modugno^{67,68}, Alvaro N. Monteiro⁶⁹, Patricia G. Moorman⁷⁰, Kirsten B. Moysich⁷¹, Roberta B. Ness⁷², Heli Nevanlinna⁷³, Håkan Olsson⁷⁴, N. Charlotte Onland-Moret⁷⁵, Sue K. Park^{76,77,78}, James Paul³⁵, Celeste L. Pearce^{79,80}, Tanja Pejovic^{81,82}, Catherine M. Phelan⁶⁹, Malcolm C. Pike^{80,83}, Susan J. Ramus^{84,85}, Elio Riboli⁸⁶, Cristina Rodriguez-Antona^{7,8}, Isabelle Romieu⁸⁷, Dale P. Sandler⁸⁸, Joellen M. Schildkraut⁸⁹, Veronica W. Setiawan⁹⁰, Kang Shan⁹¹, Nadeem Siddiqui⁹², Weiva Sieh^{93,94}, Meir J. Stampfer⁹⁵, Rebecca Sutphen⁹⁶, Anthony J. Swerdlow^{97,98}, Lukasz M. Szafron⁹⁹, Soo Hwang Teo^{100,101}, Shelley S. Tworoger^{69,102}, Jonathan P. Tyrer¹⁰³, Penelope M. Webb¹⁰⁴, Nicolas Wentzensen¹⁰⁵, Emily White^{106,107}, Walter C. Willett^{20,95,108}, Alicja Wolk^{109,110}, Yin Ling Woo¹¹¹, Anna H. Wu⁹⁰, Li Yan¹¹², Drakoulis Yannoukakos¹¹³, Georgia Chenevix-Trench¹¹⁴, Thomas A. Sellers⁶⁹, Paul D.P. Pharoah^{24,103}, Wei Zheng¹, and Jirong Long¹

¹Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. ²Department of Molecular Physiology & Biophysics, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee. ³Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. ⁴Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina. ⁵Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, California. ⁶Gynaecology Unit, Royal Marsden Hospital, London, United Kingdom. ⁷Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ⁸Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. ⁹Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway. ¹⁰Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. ¹¹Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom. ¹²Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ¹³Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. ¹⁴Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. ¹⁵Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁶Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ¹⁷Department of Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. ¹⁸University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, New Mexico. ¹⁹Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada. ²⁰Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ²¹Obstetrics and Gynecology Epidemiology Center,

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ²²Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia. ²³Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. ²⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. ²⁵Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah. ²⁶Gynaecology Research Unit, Hannover Medical School, Hannover, Germany. ²⁷Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. ²⁸Vanderbilt Epidemiology Center, Vanderbilt Genetics Institute, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee. ²⁹David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California. ³⁰Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. ³¹The Center for Bioinformatics and Functional Genomics at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. ³²Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia. ³³Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. ³⁴Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ³⁵The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. ³⁶Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota. ³⁷Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California.

Abstract

DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study ($N = 1,595$) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of $P < 7.94 \times 10^{-7}$. Of them, 87 were located at GWAS-identified EOC susceptibility

regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely *MAPT*, *HOXB3*, *ABHD8*, *ARHGAP27*, and *SKAP1*. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression.

Significance: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.

³⁸Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ³⁹Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. ⁴⁰Department of Epidemiology, University of Washington, Seattle, Washington. ⁴¹Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany. ⁴²Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huysens-Stiftung/Knappschaft GmbH, Essen, Germany. ⁴³Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas. ⁴⁴Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. ⁴⁵Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. ⁴⁶The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ⁴⁷Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada. ⁴⁸Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. ⁴⁹Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada. ⁵⁰OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada. ⁵¹Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. ⁵²Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina. ⁵³Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. ⁵⁴Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ⁵⁵CHUM Research Centre (CRCHUM) and Département de Médecine Sociale et Préventive, Université de Montréal, Montréal, Quebec, Canada. ⁵⁶VIB Center for Cancer Biology, VIB and Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium. ⁵⁷Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada. ⁵⁸Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. ⁵⁹Gynecologic Oncology, Laura and Isaac Pearlmuter Cancer Center, NYU Langone Medical Center, New York, New York. ⁶⁰Department of Gynaecology, Radboud Institute for Molecular Life sciences, Radboud University Medical Center, Nijmegen, the Netherlands. ⁶¹Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan. ⁶²Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ⁶³Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada. ⁶⁴Department Surgery & Cancer, Imperial College London, London, United Kingdom. ⁶⁵Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom. ⁶⁶MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, United Kingdom. ⁶⁷Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania. ⁶⁸Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of

Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. ⁶⁹Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida. ⁷⁰Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina. ⁷¹Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York. ⁷²School of Public Health, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas. ⁷³Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ⁷⁴Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden. ⁷⁵Julius Center for Health Sciences and Primary Care, University Utrecht, UMC Utrecht, Utrecht, the Netherlands. ⁷⁶Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. ⁷⁷Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea. ⁷⁸Cancer Research Institute, Seoul National University, Seoul, Korea. ⁷⁹Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan. ⁸⁰Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California. ⁸¹Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon. ⁸²Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. ⁸³Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York. ⁸⁴School of Women's and Children's Health, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia. ⁸⁵The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia. ⁸⁶Imperial College London, London, United Kingdom. ⁸⁷Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France. ⁸⁸Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina. ⁸⁹Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia. ⁹⁰Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. ⁹¹Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China. ⁹²Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom. ⁹³Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. ⁹⁴Department of Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. ⁹⁵Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. ⁹⁶Epidemiology Center, College of Medicine, University of South Florida, Tampa, Florida. ⁹⁷Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom. ⁹⁸Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom. ⁹⁹Department of Immunology, Maria Skłodowska-Curie Institute - Oncology Center, Warsaw, Poland. ¹⁰⁰Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia. ¹⁰¹Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur, Malaysia. ¹⁰²Research Institute and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ¹⁰³Centre for Cancer Genetic Epidemiology, Department of

Introduction

Ovarian cancer is one of the most deadly cancers among women in the United States (1) and around the world (2). Approximately 90% of ovarian neoplasms are epithelial ovarian cancer (EOC; ref. 1), a heterogeneous disease that can be categorized into five major histotypes (1). Genetic factors have an important impact on EOC etiology. Large-scale genome-wide association studies (GWAS) have identified 34 common risk loci for EOC to date (3). Of these, 27 are specific to the most common histotype, serous EOC (3). However, known loci are estimated to account for only a small proportion (~6.4%) of overall EOC risk (3). In addition, causal genes at most loci and the underlying pathogenic mechanisms are yet to be identified.

In addition to genetic susceptibility, cancer initiation and progression are also influenced by epigenetics (4). The most extensively studied epigenetic marker is DNA methylation, which regulates chromatin structure (5) and gene expression (6). DNA methylation patterns are generally programmed during normal development (7). Abnormal methylation has been observed in multiple malignancies, including EOC (8, 9). Studies have identified multiple DNA methylation markers in tumor tissue samples as prognostic biomarkers for EOC (10, 11). Several studies have also investigated the potential of DNA methylation from white blood cells to be early detection biomarkers for EOC and identified nearly 100 candidate CpGs for EOC risk (12–15). To date, only two CpGs, cg10061138 and cg10636246, were consistently observed across different studies (12–15). The lack of consistent findings may reflect the small sample sizes of prior studies (200–400 cases), an inadequate consideration of potential confounders and reverse causation.

DNA methylation is impacted by both environmental factors and genetic factors (6). High-throughput methylome profiling in both twin and familial studies has shown that methylation levels for a large number of CpGs are heritable (16, 17). Furthermore, several studies (18, 19) have revealed a large number of methylation quantitative trait loci (meQTL) in white blood cells. These results suggest that DNA methylation levels could be partially predicted by genetic variants. Indeed, meQTL single-nucleotide polymorphisms (SNP) appear to predict DNA methylation levels in white blood cells and the predicted methylation levels associated with disease risk (20, 21). However, these studies only used single meQTL SNPs to predict methylation levels for each CpG site. The prediction accuracy is low because meQTL SNPs explain only a small proportion of variance. In this study, we used a novel approach

to overcome this limitation by building and validating statistical models to predict methylation levels based on multiple genetic variants in reference datasets. The prediction models were then applied to genetic data from 22,406 cases and 40,941 controls to test the hypothesis that genetically predicted DNA methylation is associated with EOC risk. This approach could overcome the selection bias and reverse causation in conventional epidemiologic studies of DNA methylation and disease because alleles are randomly assigned during gamete formation.

Materials and Methods

Building DNA methylation prediction models using data from the Framingham Heart Study

Genome-wide DNA methylation and genotype data from white blood cell samples from individuals in the Framingham Heart Study (FHS) Offspring Cohort were obtained from dbGaP (accession numbers phs000724 and phs000342, respectively). Detailed descriptions of the FHS Offspring Cohort have been previously reported (22). Genotyping was conducted using the Affymetrix 500K mapping array and imputation was performed with the 1000 Genome Phase I (version 3) data as reference. Only SNPs with a minor allele frequency (MAF) of ≥ 0.05 and an imputation quality (R^2) of ≥ 0.80 were used to build prediction models. Genome-wide DNA methylation profiling was generated using the Illumina HumanMethylation450 BeadChip. We used the R package "minfi" (23) to filter low-quality methylation probes, evaluate cell type composition for each sample, and estimate methylation beta-values. Methylation data were then quantile-normalized across samples, rank-normalized to remove potential outliers, and then regressed on covariates including age, sex, cell-type composition, and top ten principal components (PC) to eliminate potential experimental confounders and population structure. Finally, 1,595 unrelated individuals of European descent (883 females and 712 males, mean \pm SD of age: 66.3 ± 9.0) with both genetic and DNA methylation data were included in prediction model building.

Using the elastic net method ($\alpha = 0.50$) implemented in the R package "glmnet" (24), we built a statistical model to predict methylation levels for each CpG site using the SNPs within its 2 megabase (Mb) flanking region. For each model, we performed 10-fold cross-validation as internal validation and calculated the squared value of the correlation coefficient between measured and predicted methylation levels, that is, R_{FHS}^2 , to estimate prediction performance.

Oncology, University of Cambridge, Cambridge, United Kingdom. ¹⁰⁴Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ¹⁰⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. ¹⁰⁶Fred Hutchinson Cancer Research Center, Seattle, Washington. ¹⁰⁷Department of Epidemiology, University of Washington, Seattle, Washington. ¹⁰⁸Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. ¹⁰⁹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ¹¹⁰Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. ¹¹¹Department of Obstetrics and Gynaecology, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia. ¹¹²Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China. ¹¹³Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokri-

tos", Athens, Greece. ¹¹⁴Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Jirong Long, Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37203-1738. Phone: 615-343-6741; Fax: 615-343-0719; E-mail: jirong.long@vumc.org

doi: 10.1158/0008-5472.CAN-18-2726

©2018 American Association for Cancer Research.

Evaluation of model performance using data from the Women's Health Initiative

Using data from white blood cell samples from 883 independent healthy women of European descent from the Women's Health Initiative (WHI), we evaluated the performance of the established genetic prediction models. Data from the WHI samples were obtained from dbGaP (accession numbers phs001335, phs000675, and phs000315). Genotyping was conducted using the HumanOmniExpress and HumanOmni1-Quad array. The data were quality controlled and imputed using similar criteria and procedures as those described for the FHS data. The Illumina HumanMethylation450 BeadChip was used to profile DNA methylation and the data were then processed using the same pipeline as that for the FHS data. The prediction models established in FHS were applied to the genetic data in WHI to predict methylation levels at each CpG site for each sample. Then, the predicted and measured methylation levels for each CpG site were compared by estimating the squared value of the Spearman correlation coefficient, that is, R_{WHI}^2 .

We used the following criteria to select prediction models for association analyses: (i) a prediction R_{FHS}^2 of ≥ 0.01 (correlation between measured and predicted methylation levels of ≥ 0.10) in the FHS; (ii) a R_{WHI}^2 of ≥ 0.01 in the WHI; and (iii) methylation probes on the HumanMethylation450K BeadChip not overlapping with any SNP included in the dbSNP database (Build 151; ref. 25), considering that SNPs on the probes may have a potential impact on the methylation level estimation (19). In total, models for 63,000 CpGs met these requirements and were included in the downstream association analyses for EOC risk.

Association between genetically predicted DNA methylation and EOC risk

MetaXcan (26) was used to estimate the associations between genetically predicted methylation levels and EOC risk. The methodology of MetaXcan has been described elsewhere (26, 27). Briefly, the following formula was used to evaluate the association Z-score:

$$Z_m \approx \sum_{s \in \text{Model}_m} w_{sm} \frac{\hat{\sigma}_s}{\hat{\sigma}_m} \frac{\hat{\beta}_s}{\text{se}(\hat{\beta}_s)}$$

In the formula, w_{sm} represents the weight of SNP s on the methylation level of the CpG site m , estimated by the prediction model. $\hat{\sigma}_s$ and $\hat{\sigma}_m$ are the evaluated variances of SNP s and the predicted methylation level at CpG site m , respectively. $\hat{\beta}_s$ and $\text{se}(\hat{\beta}_s)$ represent the beta coefficient and standard error of SNP s on EOC risk, respectively. For this study, the correlations between predicting SNPs for all CpGs were evaluated using the data from European participants in the 1000 Genomes Project Phase 3.

Beta coefficient $\hat{\beta}_s$ and standard error $\text{se}(\hat{\beta}_s)$ for the association between SNP s and EOC risk were obtained from the Ovarian Cancer Association Consortium (OCAC), which includes 22,406 EOC cases and 40,941 controls of European ancestry (3). Details of this consortium have been described elsewhere (3). For patients with EOC, some may have had neo-adjuvant chemotherapy before surgery. They were not included in subtype analyses but included in the analyses for overall EOC risk (3). Cases were classified as one of five histotypes: high-grade serous ($n = 13,037$), endometrioid ($n = 2,810$), mucinous invasive ($n = 1,417$), clear cell ($n = 1,366$), or low-grade

serous ($n = 1,012$). In addition, there were 2,764 EOC cases that could not be categorized into any histotypes. Genotyping was conducted using OncoArray and other GWAS arrays, followed by imputation, with the 1000 Genomes Project Phase 3 as reference. Association analyses were conducted within each dataset (different GWAS arrays) and the results were combined by a fixed-effect inverse-variance meta-analysis. Among the 751,157 SNPs included in the prediction models for 63,000 CpGs, summary statistics for associations between 751,031 (99.98%) of these SNPs and EOC risk were available from the OCAC. A total of 62,938 CpGs, corresponding to these 751,031 SNPs, were included in the final analyses. This study was approved by the OCAC Data Access Coordination Committee.

For risk analyses in OCAC, we used a Bonferroni-corrected threshold of $P < 7.94 \times 10^{-7}$ ($0.05/62,938$) for statistical significance in assessing the association between each of the 62,938 CpGs and EOC risk. Associations of predicted methylation and EOC risk identified in the OCAC data were further evaluated using the summary statistics of two GWAS studies of ovarian cancer in the UK Biobank (28). However, the sample size of the EOC cases is very small, with only 440 histologically diagnosed and 579 self-reported ovarian cancer cases among nearly 337,000 unrelated individuals of European descent. GWAS analyses were conducted using a linear regression model. The summary statistics data are available at <https://sites.google.com/broadinstitute.org/ukbbgwasresults/home>.

We estimated whether the identified associations of predicted methylation with EOC risk were independent of GWAS-identified EOC susceptibility variants. For each SNP included in the prediction model, we used GCTA-COJO (29) to evaluate the $\hat{\beta}_s$ and $\text{se}(\hat{\beta}_s)$ with EOC risk after adjusting for the GWAS-identified variants for EOC. Then, we reconducted the MetaXcan analyses to investigate the associations of the predicted methylation levels with EOC risk conditioning on the GWAS-identified EOC risk variants. We also performed stratification analyses by six EOC histotypes and estimated the heterogeneity across histotype groups by using Cochran Q test.

Functional annotation of methylation markers

Using ANNOVAR (30), all 62,938 investigated CpGs were classified into 11 functional categories: upstream, transcription start site upstream 1,500 bp (TSS1500), TSS200, 5'-untranslated region (UTR), exonic, intronic, 3'-UTR, downstream, intergenic, noncoding RNA (ncRNA) exonic and ncRNA intronic.

Correlation analyses of DNA methylation with gene expression in white blood cells

For those 89 CpGs with predicted methylation levels associated with EOC risk, we investigated those methylation levels in relation to the expression levels of genes flanking these CpGs. Individual-level DNA methylation and gene expression data of white blood cell samples from the FHS Offspring Cohort were accessed from dbGaP (accession numbers phs000724 and phs000363). The details of the Offspring Cohort of the FHS, the DNA methylation data and gene expression data have been described previously (22, 31). In total, 1,367 unrelated participants with both methylation and gene expression data were included in correlation analyses. A threshold of $P < 0.05$ was used to determine a nominally significant correlation between methylation level and gene expression level. In addition, using data from the FHS, we

investigated whether the methylation of those 89 EOC-associated CpGs could regulate the expression of 19 homologous recombination (HR) genes (32, 33).

Association analyses of genetically predicted gene expression with EOC risk

For genes with expression levels nominally correlated with methylation levels of CpGs that were associated with EOC, we investigated whether genetically predicted gene expression levels were associated with EOC risk following methods described elsewhere (27). Briefly, genome-wide genetic and gene expression data from 6,124 different tissue samples (donated by 369 participants of European ancestry) included in the Genotype-Tissue Expression (GTEx) release 6 (34) were used to build genetic models for gene expression prediction by following the elastic net method (27). The models were then applied to the OCAC data to estimate the associations between genetically predicted gene expression levels and EOC risk by using MetaXcan (26). We used Bonferroni correction to declare statistically significant associations.

Consistent directions of associations across methylation, gene expression, and EOC risk

To infer potential mechanisms underlying the identified associations between DNA methylation and EOC risk, we conducted integrative analyses of the association results between predicted CpG methylation and EOC risk, correlations between CpG methylation and gene expression, and associations between gene expression and EOC risk. First, we examined whether the association directions among DNA methylation, gene expression and EOC risk were consistent. Then, we evaluated whether genetically predicted methylation might mediate associations between gene expression and EOC risk. Briefly, for each gene we used GCTA-COJO (35) to generate modified summary statistics of associations between SNPs in its expression prediction models and EOC

risk after adjusting for SNPs included in the methylation prediction model of its corresponding CpG site. Finally, the prediction models of each gene were applied to the updated summary statistics using MetaXcan (26) to estimate the association between genetically predicted gene expression and EOC risk conditioning on the effects of the genetically predicted methylation level at each corresponding CpG site.

Results

DNA methylation prediction models

Figure 1 presents the overall workflow of this study. Data from the FHS Offspring Cohort were used to create methylation prediction models for 223,959 CpGs. Of these, 81,361 showed a prediction performance (R_{FHS}^2) of ≥ 0.01 , representing at least a 10% correlation between predicted and measured methylation levels. For these 81,361 CpGs, the number of SNPs in prediction models ranged from 1 to 276, with a median of 25. Applying these 81,361 models to genetic data from the WHI, 70,269 (86.4%) models showed a correlation coefficient between predicted and measured methylation levels (R_{WHI}) of $>10\%$. Among these 70,269 CpGs, methylation probes of 7,269 on the HumanMethylation450 BeadChip overlapped with SNPs, which may have affected the estimation of the methylation levels (19). Hence, these CpGs were excluded. The remaining 63,000 CpGs were included in the downstream analyses.

Associations of genetically predicted DNA methylation with EOC risk

The prediction models were applied to the data from a GWAS of 22,406 EOC cases and 40,941 controls included in OCAC. Summary statistics of associations between 751,031 of the 751,157 SNPs, corresponding to 62,938 of the 63,000 CpGs, and EOC risk were available in OCAC. For these 62,938 CpGs, a high correlation of prediction performance between models based on FHS




Figure 1.
Study design flow chart.

Yang et al.

(R_{FHS}^2) and WHI (R_{WHI}^2) data was observed, with a Pearson correlation coefficient of 0.95. This indicates that for each of these CpGs, a same set of predicting SNPs could predict a very similar methylation level, using either FHS or WHI data.

For most of these 62,938 CpGs, a large majority of predicting SNPs were available in OCAC (e.g., for 94% of the investigated CpGs, $\geq 95\%$ of the SNPs in prediction models were available in OCAC). Supplementary Figure S1 is the Manhattan plot presenting the associations between genetically predicted methylation levels and EOC risk. Among the 62,938 CpGs, 89 were significantly associated with EOC risk at a Bonferroni-corrected threshold of $P < 7.94 \times 10^{-7}$ (Tables 1 and 2; Supplementary Table S1). Among these 89 CpGs, a higher predicted methylation level was associated with an increased risk of EOC at 48 CpGs, and with a decreased EOC risk in the other 41 CpGs. This indicates that the methylation levels were predicted to be higher for 48 CpGs and lower for 41 CpGs among EOC cases than among controls. For these 89 CpGs, we also rebuilt the prediction models only using data from females ($N = 833$) in FHS. A very high correlation was observed, with a Pearson correlation coefficient of 0.99, between the prediction performance R^2 values, based on data of all FHS participants ($N = 1,595$) and those based on females only data ($N = 833$). In the UK Biobank data, consistent associations were observed for 23 CpGs, including 12 at $P < 0.05$, and 11 additional CpGs at $P < 0.10$ (Supplementary Table S2). This relatively low replication rate is not unexpected, considering the very limited statistical power of the UK Biobank data because of a very small number of cases ($N = 400$ – 600).

Among the 89 CpGs that were associated with EOC, two reside in a genomic region on chromosome 7 that has not yet been reported for EOC risk (500Kb away from any GWAS-identified EOC susceptibility variants; Table 1). Given that there are no risk variants identified by previous GWAS on this chromosome, associations with EOC risk conditioning on proximally located risk variants could not be conducted. Among the remaining 87 CpGs located in nine previously identified EOC risk loci, no associations remained significant after an adjustment for all risk SNPs in the corresponding loci. This suggests that the associations of these 87 CpGs with EOC risk were all driven by known EOC risk SNPs in these loci (Table 2; Supplementary Table S1).

Stratification analyses by EOC histotypes revealed that all 89 CpGs were associated with both serous ovarian cancer and

high-grade serous ovarian cancer. Fewer CpGs were associated with the other histotypes, including endometrioid ovarian cancer (cg25137403, cg14454907, and cg25708328), mucinous ovarian cancer (cg25137403, cg14454907, cg10086659, and cg25708328), and low-grade serous ovarian cancer (cg01572694; Supplementary Tables S3–S4). Fourteen of these 89 CpGs showed more significant associations with the serous and the high-grade serous ovarian cancers than with other histotypes, with a heterogeneity test $P < 5.62 \times 10^{-4}$, a Bonferroni-corrected threshold (0.05/89; Supplementary Table S3). Among these 89 CpGs, a significant correlation of methylation and gene expression was identified for 91 CpG-HR gene pairs, including 22 CpGs and 11 HR genes, at a Bonferroni-corrected threshold of $P < 2.96 \times 10^{-5}$ (0.05/1,691; Supplementary Table S5). Interestingly, methylation levels of three CpGs, that is, cg13568213 (9q34.2), cg10900703 (10p12.31), and cg23659289 (17q21.31) showed a strong correlation with the expression level of the *ATM* gene.

DNA methylation affecting EOC risk through regulating expression of a neighbor gene

For those 89 CpGs with predicted methylation levels associated with EOC risk, we conducted correlation analyses with gene expressions for 63 pairs of CpG-gene, including 58 CpGs with 21 flanking genes that were annotated by ANNOVAR (30). Nominally significant correlations were observed for 26 CpG-gene pairs, including 26 CpGs and 12 genes, at $P < 0.05$ (Table 3; Supplementary Table S6). Among them, the most significant correlation was observed between the increased methylation at the CpG cg19139618, located in the promoter region of the *SKAP1* gene, and the expression level of *SKAP1*, with a P value of 2.98×10^{-15} (Table 3). In addition, increased methylation levels at two CpGs, cg10900703 and cg04231319, located in the introns of the *MLLT10* gene, were significantly correlated with an increased expression of *MLLT10*, with P values of 2.79×10^{-11} and 1.36×10^{-5} , respectively. For the two CpGs located in a putative novel locus, a higher methylation level for one of them, cg03634833, was correlated with a lower expression of the *ADAP1* gene in this locus, with a P value of 2.99×10^{-3} (Supplementary Table S6). As expected, methylation levels at CpGs located in promoter regions (TSS1500 and TSS200) were more likely to be negatively correlated with expressions of proximal genes. Nearly all CpGs located in downstream or in 3'UTR showed a negative

Table 1. Two novel methylation-EOC associations for two CpGs located at a genomic region not yet reported for EOC risk

CpG	Chr	Position	Closest gene	Classification	R_{FHS}^{2a}	Histotype	Z score	OR (95% CI) ^b	P
cg18139273	7	962,582	<i>ADAP1</i>	Intronic	0.01	Overall	-4.95	0.51 (0.39-0.66)	7.25×10^{-7}
						Serous ^c	-4.87	0.46 (0.34-0.63)	1.13×10^{-6}
						High-grade serous	-4.83	0.46 (0.33-0.63)	1.39×10^{-6}
						Endometrioid	-1.78	0.59 (0.33-1.06)	0.08
						Mucinous	-0.99	0.67 (0.30-1.49)	0.32
						Clear cell	-1.87	0.46 (0.21-1.04)	0.06
						Low-grade serous	-0.97	0.62 (0.24-1.63)	0.33
						Overall	-5.00	0.84 (0.79-0.90)	5.81×10^{-7}
						Serous ^c	-4.85	0.83 (0.77-0.89)	1.21×10^{-6}
						High-grade serous	-4.85	0.82 (0.76-0.89)	1.25×10^{-6}
cg03634833	7	965,534	<i>ADAP1</i>	Intronic	0.09	Endometrioid	-2.21	0.83 (0.71-0.98)	0.03
						Mucinous	-1.40	0.87 (0.71-1.06)	0.16
						Clear cell	-1.76	0.84 (0.69-1.02)	0.08
						Low-grade serous	-0.87	0.91 (0.73-1.13)	0.39

Abbreviation: CI, confidence interval.

^aCorrelation between predicted and measured methylation levels.

^bOR per SD increase in genetically predicted methylation level.

^cIncluding high-grade serous and low-grade serous ovarian cancers.

Table 2. Selected^a seven methylation-EOC associations driven by previously identified EOC-risk SNPs

CpG	Chr	Position	Closest gene	Classification	Z score	OR (95% CI) ^b	P value	R _{FHS} ² ^c	EOC risk SNPs	Distance to the risk SNPs (kb)	P value adjusted for the risk SNPs
cg25137403	2	177,022,172	<i>HOXD4; HOXD3</i>	Intergenic	7.51	1.24 (1.18-1.32)	5.96×10^{-14}	0.15	rs6755777; rs711830	21;15	0.09
cg26405475	3	156,324,038	<i>SSR3; TIPARP-AS1</i>	Intergenic	-9.45	0.69 (0.64-0.74)	3.42×10^{-21}	0.07	rs62274041	111	0.34
cg08478672	8	129,374,295	<i>MIR208; LINC00824</i>	Intergenic	5.08	1.29 (1.17-1.42)	3.81×10^{-7}	0.06	rs1400482	167	0.05
cg14653977	9	136,038,692	<i>GBG11</i>	Intergenic	5.99	1.75 (1.46-2.09)	2.04×10^{-9}	0.03	9;136138765 ^d	100	0.09
cg04231519	10	21,824,447	<i>MLL110</i>	Intronic	-5.72	0.88 (0.84-0.92)	1.05×10^{-8}	0.19	rs144962376	54	0.94
cg07067577	17	43,506,829	<i>ARHGAP27</i>	3'UTR	-7.49	0.73 (0.67-0.79)	6.86×10^{-14}	0.07	rs1879586	60	0.01
cg21956434	19	17,377,697	<i>BABAM1</i>	TSS1500	7.07	1.13 (1.09-1.17)	1.53×10^{-12}	0.34	rs4808075	12	0.39

Abbreviation: CI, confidence interval.

^aSelected from 87 CpG-EOC associations. For each locus, only the most significantly associated CpG was presented. Complete list of results for all CpG-EOC associations is available in Supplementary Table S1.^bOR per SD increase in genetically predicted methylation level.^cCorrelation between predicted and measured methylation levels.^dGRCh37 position.

regulatory effect on expression of neighbor genes. For CpGs residing in intronic regions, both positive and negative correlations were observed.

For the 12 genes with expression levels correlated with DNA methylation, expression prediction models were built for seven, with a prediction performance (R^2) of ≥ 0.01 , using GTEx data. Applying these seven models to the OCAC data, genetically predicted expression levels of three genes, namely *MAPT*, *HOXB3*, and *ABHD8*, were significantly associated with EOC risk after Bonferroni correction (Table 4). At 17q21.31 and 17q21.32, higher predicted expression levels of *MAPT* and *HOXB3* were associated with a decreased EOC risk, with P values of 3.74×10^{-4} and 2.00×10^{-7} , respectively. After adjusting for established EOC risk SNPs, the associations between these two genes and EOC risk disappeared. At 19p13.11, an increased predicted expression level for *ABHD8* was associated with an increased EOC risk, with a P value of 9.93×10^{-6} . Conditioning on the EOC risk SNP in this locus, the association disappeared as well (Table 4). Of the five genes without prediction models, two were previously reported to be associated with EOC susceptibility, including *SKAP1* (36) and *ARHGAP27* (37).

We integrated the results for the association between DNA methylation and EOC risk, the correlation between DNA methylation and gene expression, and the association between gene expression and EOC risk. We identified consistent directions of associations across seven CpGs, including cg18878992, cg00480298, cg07368061, cg01572694, cg14285150, cg24672833, and cg17941109, three genes, including *MAPT*, *HOXB3* and *ABHD8*, and EOC risk (Table 5). The mechanism potentially underlying the associations of methylation at these seven CpGs and EOC risk may be their regulatory function on expression of these three genes. Among them, increased methylation at the CpG site cg14285150 was associated with an increased *HOXB3* expression ($P = 8.44 \times 10^{-5}$) and decreased EOC risk ($P = 5.53 \times 10^{-8}$). As expected, an increased expression of *HOXB3* was associated with a decreased EOC risk ($P = 2.00 \times 10^{-7}$). Conditioning on SNPs included in the methylation prediction model for cg14285150, the association of *HOXB3* expression and EOC risk disappeared ($P = 0.51$; Table 5).

Expression prediction models could not be built for *SKAP1* at 17q21.32 and *ARHGAP27* at 17q21.31 in this study. Hence, these two genes could not be investigated in association with EOC risk. However, higher expression levels of these two genes have been previously reported to be associated with an increased risk of EOC (36, 37). This is expected, based on the association results of DNA methylation with EOC risk and DNA methylation with gene expression (Table 5). For example, a higher methylation at cg19139618 was associated with a lower expression of *SKAP1* ($P = 2.98 \times 10^{-15}$) and lower EOC risk ($P = 7.08 \times 10^{-7}$). Hence, the potential mechanism underlying the association between cg19139618 and EOC risk may be the downregulation effects on *SKAP1* expression (Table 5).

Discussion

In this large study, we identified 89 CpGs that were significantly associated with EOC risk, including two CpGs located in a novel genomic region that have not yet been reported as a susceptibility locus for EOC. Integrating genetic, methylation, and gene expression data suggested that methylation at 12 of 89 CpGs may exert their impacts on EOC risk through regulating the expression of

Yang et al.

Table 3. Selected^a correlations between methylation levels at 26 CpGs and expression levels of 12 genes; data from the FHS

CpG	Chr	Position	Classification	Closest gene	Rho	P
cg25137403	2	177,022,172	Downstream	<i>HOXD4</i>	-0.06	0.02
cg22211092	3	156,361,584	Downstream	<i>SSR3</i>	0.09	9.43×10^{-4}
cg03634833	7	965,534	Intronic	<i>ADAP1</i>	-0.08	2.99×10^{-3}
cg14653977	9	136,038,692	Intronic	<i>GBG71</i>	-0.06	0.02
cg24267699	9	136,151,359	TSS1500	<i>ABO</i>	-0.09	8.07×10^{-4}
cg10900703	10	21,824,407	Intronic	<i>MLLT10</i>	0.18	2.79×10^{-11}
cg23659289	17	43,472,725	3'UTR	<i>ARHGAP27</i>	-0.19	9.89×10^{-13}
cg07368061	17	44,090,862	Intronic	<i>MAPT</i>	0.08	2.02×10^{-3}
cg19139618	17	46,504,791	Intronic	<i>SKAP1</i>	-0.21	2.98×10^{-15}
cg14285150	17	46,659,019	Intronic	<i>HOXB3</i>	0.11	8.44×10^{-5}
cg22311200	17	46,695,514	Downstream	<i>HOXB8</i>	0.08	2.59×10^{-3}
cg17941109	19	17,407,198	Intronic	<i>ABHD8</i>	-0.06	0.03

^aSelected from correlations between 26 CpGs and 12 genes. For each gene, only the most significantly correlated CpG is presented. Complete list of results for all CpG-EOC associations is available in Supplementary Table S6.

five genes. These results provide new insights into the regulatory pathways that connect genetics, epigenetics, gene expression, and EOC risk.

We identified two methylation markers, cg18139273 and cg03634833, located at 7p22.3, a novel genomic region that had not been reported as a risk locus for EOC. Both CpGs reside in the third intron of the first transcript of the *ADAP1* gene, which encodes an ADP-ribosylation factor GTPase-activating protein (ArfGAP) with dual PH domains 1. *ADAP1* functions as a scaffolding protein in several signal transduction pathways. It is highly expressed in neurons, where it has roles in neuronal differentiation and neurodegeneration (38). This gene has also been reported to be involved in mitochondrial function (39), and is a target of the ErbB4 transcription factor in mammary epithelial cells (40). In this study, we found that a higher methylation level at cg03634833 was significantly correlated with a lower *ADAP1* expression, which was associated with a nonsignificantly decreased EOC risk. Thus, methylation at cg03634833 might be associated with EOC risk through a regulatory function on *ADAP1* expression, or through other unidentified mechanisms.

Integrating the results of the association between DNA methylation and EOC risk, the correlation between DNA methylation and gene expression, and the association between gene expression and EOC risk, we observed consistent directions of associations across 12 CpGs, five genes, and EOC risk. For the *MAPT* gene (17q21.31), an increased methylation at two CpGs located in its exons, cg18878992 and cg00480298, were associated with a decreased *MAPT* expression and increased EOC risk. For the other CpG site, cg07368061, located at the first intron of *MAPT*, its increased methylation was associated with a higher *MAPT* expression and lower EOC risk. As expected, an increased *MAPT* expression was associated with decreased EOC risk. The *MAPT* gene has been linked to multiple neurodegenerative disorders, including progressive supranuclear palsy (41), Parkinson's disease (42, 43), and Alzheimer's disease (42). In addition, a higher expression of a *MAPT* protein

Table 4. Three genes with genetically predicted expression levels associated with EOC risk

Region	Gene	Type	Z score	P	P_{adj}^a	R^{2b}
17q21.31	<i>MAPT</i>	Protein	-3.56	3.74×10^{-4}	0.40	0.08
17q21.32	<i>HOXB3</i>	Protein	-5.20	2.00×10^{-7}	0.71	0.12
19p13.11	<i>ABHD8</i>	Protein	4.42	9.93×10^{-6}	0.59	0.23

^aAdjusting for the EOC risk SNPs in the corresponding locus.

^bCorrelation between predicted and measured gene expression levels.

isoform (<70 kDa) was correlated with a lower sensitivity to taxanes in breast cancer cells (44). Methylation of the miRNA *miR-34c-5p* was shown to regulate the *MAPT* expression, which was related to paclitaxel resistance in gastric cancer cells (45).

Increased methylation of three CpGs in the first intron of the *HOXB3* gene (17q21.32), cg01572694, cg14285150, and cg24672833, were associated with an increased expression of *HOXB3* and decreased EOC risk. As expected, an increased *HOXB3* expression was associated with decreased EOC risk. A previous study reported that the expression of *HOXB3* was upregulated in EOC cell lines compared with normal samples (46). However, this study only included 5 patients and the results have not been replicated by an independent study. On the other side, we investigated the genetically predicted methylation levels in DNA from white blood cells, but not in ovary or fallopian tube epithelial cells. It is possible that the correlation between methylation levels of these CpGs and *HOXB3* expression are different in ovary epithelial cells and white blood cells. For example, in the 5'UTR of *HOXB3*, a higher methylation at the CpG cg12910797 was significantly associated with an increased EOC risk. The increased methylation of this CpG was not correlated with the expression of *HOXB3* in white blood cells samples from the FHS (Spearman correlation coefficient $r = -0.02$; $P = 0.43$). Higher methylation of this CpG was significantly correlated with a decreased *HOXB3* expression in ovarian serous cystadenocarcinoma samples from the Cancer Genome Atlas (TCGA) (Spearman correlation coefficient $r = -0.27$; $P = 2.01 \times 10^{-6}$; http://gdac.broadinstitute.org/runs/analyses_2016_01_28/reports/cancer/OV-TP/Correlate_Methylation_vs_mRNA/nozzle.html).

The higher methylation of the CpG site cg17941109, located at the second intron of the *ABHD8* gene, was associated with a lower *ABHD8* expression and a lower EOC risk. This is consistent with the results of two recent studies that showed that a higher expression level of this gene was associated with an increased risk of EOC (47, 48). This gene is located at 19p13.11, a susceptibility locus for both ovarian and breast cancers. Interestingly, in our unpublished data, the increased genetically predicted methylation level at cg17941109 was associated with decreased breast cancer risk, and the genetically predicted expression of *ABHD8* was associated with an increased breast cancer risk. Increasing evidence also suggests that this protein family (ABHD) has a physiologic significance in metabolism and disease (49).

For the *ARHGAP27* gene, increased methylation of two CpGs in the promoter region, cg16281322 and cg25708777, and one CpG in the 3'-UTR, cg07067577, were associated with lower expression

Table 5. Consistent directions of associations across CpG methylation, gene expression, and EOC risk for 12 CpGs and five genes

CpG	Chr	Position	Gene	Classification	CpG vs. EOC risk		CpG vs. Gex		Gex vs. EOC risk		Adjusted ^a Gex vs. EOC risk	
					Dir	P	Dir	P	Dir	P	Dir	P
cg18878992	17	43,974,344	<i>MAPT</i>	5'UTR	+	8.85×10^{-13}	-	2.64×10^{-3}	-	3.74×10^{-4}	-	0.48
cg00480298	17	44,068,857	<i>MAPT</i>	Exonic	+	6.39×10^{-9}	-	3.98×10^{-3}	-	3.74×10^{-4}	-	0.65
cg07368061	17	44,090,862	<i>MAPT</i>	Intronic	-	4.26×10^{-13}	+	2.02×10^{-3}	-	3.74×10^{-4}	-	1.00
cg01572694	17	46,657,555	<i>HOXB3</i>	Intronic	-	5.52×10^{-9}	+	7.49×10^{-3}	-	2.00×10^{-7}	-	0.82
cg14285150	17	46,659,019	<i>HOXB3</i>	Intronic	-	5.53×10^{-8}	+	8.44×10^{-5}	-	2.00×10^{-7}	-	0.51
cg24672833	17	46,659,318	<i>HOXB3</i>	Intronic	-	9.00×10^{-8}	+	5.51×10^{-3}	-	2.00×10^{-7}	-	0.41
cg17941109	19	17,407,198	<i>ABHD8</i>	Intronic	-	2.88×10^{-9}	-	0.03	+	9.93×10^{-6}	-	0.57
cg19139618	17	46,504,791	<i>SKAP1</i>	Intronic	-	7.08×10^{-7}	-	2.98×10^{-15}	+		NA ^b	
cg02957270	17	46,508,097	<i>SKAP1</i>	TSS1500	+	4.40×10^{-12}	+	0.01	+		NA ^b	
cg07067577	17	43,506,829	<i>ARHGAP27</i>	3'UTR	-	6.86×10^{-14}	-	1.20×10^{-3}	+		NA ^b	
cg16281322	17	43,510,478	<i>ARHGAP27</i>	TSS200	-	6.82×10^{-13}	-	1.14×10^{-9}	+			
cg25708777	17	43,510,841	<i>ARHGAP27</i>	TSS1500	-	4.61×10^{-13}	-	4.11×10^{-8}	+			

Abbreviations: Dir, direction of association/correlation; Gex, gene expression.

^aAdjusting for all the predicting SNPs included in prediction models of corresponding CpGs.

^b*SKAP1* and *ARHGAP27* are previously identified EOC-susceptibility genes.

level of *ARHGAP27* and lower EOC risk. For the *SKAP1* gene, a higher methylation at the CpG cg02957270, located at the promoter region, was associated with a higher expression level and increased EOC risk. Increased methylation of the other intronic CpG, cg19139618, was associated with a lower *SKAP1* expression and a decreased EOC risk. In this study, the associations of expression levels of these two genes and EOC risk could not be investigated because the prediction models for them could not be built. However, two large GWAS studies have identified these two genes as EOC susceptibility genes with solid experimental evidence (36, 37). Differential expression analyses showed a significantly higher expression of *ARHGAP27* in ovarian cancer than in normal cells (37). It is suggested that the *ARHGAP27* gene may play a role in carcinogenesis through the dysregulation of Rho/Rac/Cdc42-like GTPases (50). The expression of *SKAP1* was significantly greater in ovarian cancer cells when compared with primary human ovarian surface epithelial cells (36). Our study is the first to suggest that these two genes may be associated with EOC risk through methylation regulation.

Several epidemiologic studies have investigated the associations of CpG methylation and EOC risk in white blood cells and tumor tissue samples (12–15). Approximately 100 CpGs have been identified to be associated with EOC risk. However, only two CpGs, cg10061138 and cg10636246, showed consistent association directions in two or more studies. In this study, prediction models could not be built for these two CpGs; hence, neither could be investigated in association with EOC risk. Among the remaining 98 reported CpGs, reliable prediction models were built for only 20 of them and only two, cg19399532 and cg21870884, could be replicated at $P < 0.10$, with the same association directions as previously reported. Such a low replication rate is not unexpected because of several potential limitations in traditional epidemiologic studies, which include possible false associations because of small sample size, lack of validation in other studies, potential confounders, and reverse causation.

The methodology of this study is similar to that of transcriptome-wide association studies (TWAS), in which gene expression prediction models are established and applied to GWAS data to investigate genetically predicted gene expression in association with various diseases and traits. Of the five genes identified in this study, the expression levels of two, *HOXB3* and *ABHD8*, were significantly associated with EOC risk at the Bonferroni-corrected threshold ($P < 2.2 \times 10^{-6}$) in our previous TWAS study for

EOC (51). The *MAPT* gene showed an association with EOC at $P = 3.74 \times 10^{-4}$ in the TWAS; however, the association did not reach the Bonferroni-corrected threshold. For *ARHGAP27* and *SKAP1*, gene expression prediction models could not be built, and they were not investigated in the TWAS. Expression levels for these two genes were reported to be associated with EOC (36, 37). Some genes identified in TWAS were not tested in this study because the methylation prediction models could not be built for CpGs flanking them. In addition, except DNA methylation, there are other biological processes that regulate gene expression. The regulation of DNA methylation on gene expression differs according to the locations of the CpGs. Therefore, integrating the results of methylation and gene expression analyses may help to understand the biological basis for EOC.

It would be ideal to build methylation prediction models using data from normal ovary or fallopian tube epithelial cells, but it is almost impossible to collect tissue samples from a large population of healthy women. However, as demonstrated by multiple studies, the large majority of the meQTLs identified in white blood cells were consistently detected across different tissue types (26, 52, 53). These results indicate that the genetically determined methylation at many CpGs are predictable and consistent among different tissues. Hence, it is reasonable to build methylation prediction models using data from white blood cell samples and then investigate predicted DNA methylation in association with EOC. It would be ideal to validate the findings in this study by directly measuring methylation levels in prediagnosis blood samples in prospective studies to overcome reverse causation; however, the majority of the samples included in this study were collected after cancer diagnosis. It is possible that DNA methylation regulation on gene expression differs across tissues. In this study, data in white blood cell samples were used, which is another limitation. In the association analysis of predicted gene expression with EOC risk, the models were built using data from a limited sample size of GTEx. Thus, the number of genes evaluated in our study was small. More consistent associations across methylation, gene expression, and EOC risk could be identified with a larger sample size to build gene expression prediction models.

Strengths of this study include the large number of samples in the reference dataset used in model building and that the model performance was evaluated in an independent dataset. Using genetic variants as study instruments, we can effectively overcome

Yang et al.

many limitations commonly encountered in conventional epidemiologic studies. In addition, this is the largest study of DNA methylation with EOC risk and a very stringent criterion was used, providing high statistical power to identify reliable associations between genetically predicted methylation and EOC risk. Finally, the integrative analyses of genetic, DNA methylation, and gene expression data led to the identification of consistent evidence to support the hypothesis that DNA methylation could impact EOC risk through regulating gene expression.

In summary, in the largest study conducted to date that investigates DNA methylation in association with EOC risk, we identified multiple CpGs that were significantly associated with EOC risk and proposed that several CpGs may affect EOC risk through regulating expression of five genes. Our study demonstrates the feasibility of integrating multi-omics data to identify novel biomarkers for EOC risk and brings new insight into the etiology of this malignancy.

Disclosure of Potential Conflicts of Interest

S. Banerjee is a consultant/advisory board member for AstraZeneca, Tesaro, Clovis, Roche, Gamamabs, Merck, Seattle Genetics, and Pharmamar and has provided expert testimony for AstraZeneca, Tesaro, and Roche. J.D. Brenton reports receiving a commercial research grant from Aprea and has ownership interest (including stock, patents, etc.) in Inivata Ltd. A. DeFazio reports receiving other commercial research support from AstraZeneca. P.A. Fasching reports receiving a commercial research grant from Novartis to Institution, is a consultant/advisory board member for Novartis, Roche, Celgene, Pfizer, Daiichi-Sankyo, Teva, and Puma. B.Y. Karlan is a consultant/advisory board member for Invitae Corporation. I.A. McNeish is a consultant/advisory board member for Clovis Oncology, AstraZeneca, Tesaro, and Takeda. U. Menon has ownership interest (including stock, patents, etc.) in Abocodia Pvt Ltd. Y.L. Woo has received speakers bureau honoraria from Merck Sharp and Dohme and is a consultant/advisory board member for Merck Sharp and Dohme. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: Y. Yang, A. Berchuck, H. Anton-Culver, D.G. Huntsman, W.C. Willett, P.D.P. Pharoah, W. Zheng, J. Long

Development of methodology: Y. Yang, L. Wu, D.G. Huntsman, K.B. Moysich

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Lu, X.-O. Shu, H. Anton-Culver, S. Banerjee, J. Benitez, L. Björge, J.D. Brenton, R. Butzow, I.G. Campbell, J. Chang-Claude, L.S. Cook, D.W. Cramer, A. deFazio, J.A. Doherty, T. Dörk, D.M. Eccles, D.V. Edwards, P.A. Fasching, G.G. Giles, R.M. Glasspool, E.L. Goode, M.T. Goodman, J. Gronwald, F. Heitz, M.A.T. Hildebrandt, E. Høgdall, C.K. Høgdall, S.P. Kar, B.Y. Karlan, L.E. Kelemen, L.A. Kiemeny, S.K. Kjaer, A. Koushik, D. Lambrechts, N.D. Le, D.A. Levine, L.F.A.G. Massuger, K. Matsuo, T. May, I.A. McNeish, U. Menon, F. Modugno, P.G. Moorman, K.B. Moysich, H. Nevanlinna, H. Olsson, N.C. Onland-Moret, S.K. Park, J. Paul, T. Pejovic, C.M. Phelan, M.C. Pike, S.J. Ramus, C. Rodriguez-Antona, D.P. Sandler, J.M. Schildkraut, V.W. Setiawan, K. Shan, N. Siddiqui, W. Sieh, M.J. Stampfer, R. Sutphen, A.J. Swerdlow, L.M. Szafron, S.H. Teo, S.S. Tworoger, P.M. Webb, N. Wentzensen, E. White, W.C. Willett, A. Wolk, Y.L. Woo, A.H. Wu, L. Yan, D. Yannoukakos, G. Chenevix-Trench, T.A. Sellers, W. Zheng

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Yang, L. Wu, Y. Lu, Q. Cai, A. Beeghly-Fadiel, B. Li, F. Ye, J. Dennis, R.T. Fortner, S.A. Gayther, B.Y. Karlan, D. Lambrechts, T. May, K.B. Moysich, H. Olsson, S.K. Park, J.P. Tyrer, N. Wentzensen, E. White, A. Wolk, D. Yannoukakos

Writing, review, and/or revision of the manuscript: Y. Yang, L. Wu, X. Shu, X.-O. Shu, Q. Cai, A. Beeghly-Fadiel, B. Li, F. Ye, A. Berchuck, S. Banerjee, J. Benitez, L. Björge, J. Chang-Claude, L.S. Cook, D.W. Cramer, A. deFazio, J.A. Doherty, T. Dörk, D.M. Eccles, D.V. Edwards, P.A. Fasching, R.T. Fortner, S.A. Gayther, G.G. Giles, R.M. Glasspool, M.T. Goodman, J. Gronwald, H.R. Harris, F. Heitz, M.A.T. Hildebrandt, E. Høgdall, C.K. Høgdall, S.P. Kar, B.Y. Karlan, L.E. Kelemen, L.A. Kiemeny, S.K. Kjaer, N.D. Le, L.F.A.G. Massuger,

T. May, I.A. McNeish, U. Menon, F. Modugno, A.N. Monteiro, K.B. Moysich, R.B. Ness, N.C. Onland-Moret, S.K. Park, C.L. Pearce, S.J. Ramus, E. Riboli, C. Rodriguez-Antona, I. Romieu, D.P. Sandler, J.M. Schildkraut, V.W. Setiawan, K. Shan, N. Siddiqui, W. Sieh, M.J. Stampfer, R. Sutphen, A.J. Swerdlow, S.H. Teo, S.S. Tworoger, J.P. Tyrer, P.M. Webb, N. Wentzensen, E. White, W.C. Willett, A. Wolk, Y.L. Woo, A.H. Wu, L. Yan, G. Chenevix-Trench, T.A. Sellers, W. Zheng, J. Long

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): X.-O. Shu, K. Chen, P.A. Fasching, C.K. Høgdall, S.P. Kar, B.Y. Karlan, L.A. Kiemeny, D. Lambrechts, F. Modugno, K.B. Moysich, S.J. Ramus, R. Sutphen, P.D.P. Pharoah

Study supervision: A. Berchuck, K. Chen, L.A. Kiemeny, K.B. Moysich, J. Long

Other (providing data): R.B. Ness

Acknowledgments

We thank Jing He and Marshal Younger of Vanderbilt Epidemiology Center for their help with this study. The authors wish to thank all of the individuals who took part in the study, and all of the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. Data for the FHS Offspring Cohort were obtained from dbGaP (accession numbers phs000724, phs000342, and phs000363). Data for the WHI were obtained from dbGaP (accession numbers phs001335, phs000675 and phs000315). The data analyses were conducted using the Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt University.

Acknowledgments for individual studies: **AOV:** We thank Jennifer Koziak, Mie Konno, Michelle Darago, Faye Chambers and the Tom Baker Cancer Centre Translational Laboratories; **AUS:** The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all of the women who participated in these research programs; **BEL:** We would like to thank Gilian Peuteman, Thomas Van Brussel, Annick Van den Broeck and Joke De Roover for technical assistance; **BGS:** The BGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. We thank the study staff, study participants, doctors, nurses, health care providers, and health information sources who have contributed to the study; **BVU:** The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU, which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the Vanderbilt CTSA grant UL1TR000445 from NCATS/NIH; **CAM:** This work was supported by Cancer Research UK; the University of Cambridge; National Institute for Health Research Cambridge Biomedical Research Centre; **CHA:** Innovative Research Team in University (PCSIRT) in China (IRT1076); **CHN:** We thank all members of Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital and Department of Molecular Biology, Hebei Medical University, Fourth Hospital; **COE:** Gynecologic Cancer Center of Excellence (W81XWH-11-2-0131); **CON:** The cooperation of the 32 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data; **DKE:** OCRF; **EPC:** We thank all members and investigators of the Rotterdam Ovarian Cancer Study. Dutch Cancer Society (EMC 2014-6699); **GER:** The German Ovarian Cancer Study (GER) thank Ursula Eilber for competent technical assistance; **HOC:** The study was supported by the Helsinki University Research Fund; **JGO:** JSPS KAKENHI grant; **KRA:** This study (Ko-EVE) was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 0920010); **LUN:** ERC-2011-AdG, Swedish Cancer Society, Swedish Research Council; **MAS:** We would like to thank Famida Zulkifli and Ms. Moey for assistance in patient recruitment, data collection, and sample preparation. The Malaysian Ovarian Cancer Genetic Study is funded by research grants from the Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and charitable funding from Cancer Research Initiatives Foundation; **MCC:** MCCS cohort recruitment was

funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database; **MOF**: the Total Cancer Care Protocol and the Collaborative Data Services and Tissue Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292), Merck Pharmaceuticals and the state of Florida; **NHS**: The NHS/NHSII studies thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY; **OPL**: Members of the OPAL Study Group (<http://opalstudy.qimrberghofer.edu.au/>); **RPC**: NIH (P50 CA159981, R01CA126841); **SEA**: SEARCH team, Craig Luccarini, Caroline Baynes, Don Conroy; **SIS**: The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033); **SON**: National Health Research and Development Program, Health Canada, grant 6613-1415-53; **SRO**: We thank all members of Scottish Gynaecological Clinical Trails group and SCOTROC1 investigators; **SWE**: Swedish Cancer foundation, WeCanCureCancer, and årKampMotCancer foundation; **SWH**: The SWHS is supported primarily by NIH grant R37-CA070867. We thank the participants and the research staff of the Shanghai Women's Health Study for making this study possible; **UCI**: The UCI Ovarian cancer study is supported by the NIH, NCI grants CA58860, and the Lon V Smith Foundation grant LVS-39420; **UHN**: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; **UKO**: We particularly thank I. Jacobs, M. Widschwendter, E. Wozniak, A. Ryan, J. Ford, and N. Balogun for their contribution to the study; **UKR**: Carole Pye; **VAN**: BC Cancer Foundation, VGH & UBC Hospital Foundation; **WMH**: We thank the Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, which is funded by the National Health and Medical Research Council Enabling grants 310670 and 628903 and the Cancer Institute NSW grants 12/RIG/1-17 and 15/RIG/1-16.

This project was partially supported by the development fund from the Department of Medicine at Vanderbilt University Medical Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCL07). The scientific development and funding for this project were, in part, supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium, funded by the Wellcome Trust under award 076113. The results published here are, in part, based upon data generated by The Cancer Genome Atlas Pilot Project, established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7).

The OCAC OncoArray genotyping project was funded through grants from the NIH (U19-CA148112 (to T.A. Sellers), R01-CA149429 (to C.M. Phelan), and R01-CA058598 (to M.T. Goodman); Canadian Institutes of Health Research (MOP-86727 to L.E. Kelemen and the Ovarian Cancer Research Fund to A. Berchuck). The COGS project was funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175).

Funding for individual studies: **AAS**: NIH (R01-CA142081); **AOV**: The Canadian Institutes for Health Research (MOP-86727); **AUS**: The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; **BAV**: ELAN Funds of the University of Erlangen-Nuremberg; **BEL**: National Kankerplan; **BGS**: Breast Cancer Now, Institute of Cancer Research; the ICR acknowledges NHS funding to the NIHR Biomedical Research Centre; **BVU**: Vanderbilt CTSA grant from the NIH/National Center for Advancing Translational Sciences (NCATS; ULTR000445); **CAM**: National Institutes of

Health Research Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Cancer Centre; **CHA**: Innovative Research Team at the University (PCSIRT) in China (IRT1076); **CNI**: Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012); **COE**: Department of Defense (W81XWH-11-2-0131); **CON**: NIH (R01-CA063678, R01-CA074850; R01-CA080742); **DKE**: Ovarian Cancer Research Fund; **DOV**: NIH R01-CA112523 and R01-CA87538; **EMC**: Dutch Cancer Society (EMC 2014-6699); **EPC**: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM; France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF; Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford; United Kingdom); **GER**: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ); **GRC**: This research has been cofinanced by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the European Social Fund; **GRR**: Roswell Park Cancer Institute Alliance Foundation, P30 CA016056; **HAW**: NIH (R01-CA58598, N01-CN-55424, and N01-PC-67001); **HJO**: Intramural funding; Rudolf-Bartling Foundation; **HMO**: Intramural funding; Rudolf-Bartling Foundation; **HOC**: Helsinki University Research Fund; **HOP**: Department of Defense (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, P50-CA159981, MO1-RR000056, R01-CA126841); **HUO**: Intramural funding; Rudolf-Bartling Foundation; **JGO**: JSPS KAKENHI grant; **JPN**: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; **KRA**: This study (Ko-EVE) was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (H116C1127; 0920010); **LAX**: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; **LUN**: ERC-2011-AdG 294576-risk factors cancer, Swedish Cancer Society, Swedish Research Council, Beta Kamprad Foundation; **MAC**: NIH (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; **MAL**: Funding for this study was provided by research grant R01-CA61107 from the NCI, Bethesda, MD; research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; **MAS**: Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation; **MAY**: NIH (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; **MCC**: Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC) grants number 209057, 251533, 396414, and 504715; **MDA**: DOD Ovarian Cancer Research Program (W81XWH-07-0449); **MEC**: NIH (CA54281, CA164973, CA63464); **MOF**: Moffitt Cancer Center, Merck Pharmaceuticals, the state of Florida, Hillsborough County, and the city of Tampa; **NCO**: NIH (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); **NEC**: NIH R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; **NHS**: UM1 CA186107, P01 CA87969, R01 CA49449, R01-CA67262, UM1 CA176726; **NJO**: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720) and the

Yang et al.

Cancer Institute of New Jersey; **NOR**: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway; **NTH**: Radboud University Medical Centre; **OPL**: National Health and Medical Research Council (NHMRC) of Australia (APP1025142) and Brisbane Women's Club; **ORE**: OHSU Foundation; **OVA**: This work was supported by Canadian Institutes of Health Research grant (MOP-86727) and by NIH/NCI 1 R01CA160669-01A1; **PLC**: Intramural Research Program of the National Cancer Institute; **POC**: Pomeranian Medical University; **POL**: Intramural Research Program of the National Cancer Institute; **PVD**: Canadian Cancer Society and Cancer Research Society GRePEC Program; **RBH**: National Health and Medical Research Council of Australia; **RMH**: Cancer Research UK, Royal Marsden Hospital; **RPC**: NIH (P50 CA159981, R01CA126841); **SEA**: Cancer Research UK (C490/A10119 C490/A10124); **UK**: National Institute for Health Research Biomedical Research Centres at the University of Cambridge; **SIS**: NIH, National Institute of Environmental Health Sciences, Z01 ES044005 and Z01-ES049033; **SMC**: The Swedish Research Council; **SON**: National Health Research and Development Program, Health Canada, grant 6613-1415-53; **SRO**: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589); **STA**: NIH grants U01 CA71966 and U01 CA69417; **SWE**: Swedish Cancer foundation, WeCanCureCancer and ärKampMotCancer foundation; **SWH**: NIH (NCI) grant R37-CA070867; **TBO**: NIH (R01-CA106414-A2), American Cancer Society (CRTG-00-196-01-CCE), Department of Defense (DAMD17-98-1-8659), Celma Mastery Ovarian Cancer Foundation; **TOR**: NIH grants R01 CA063678 and R01 CA063682; **UCI**: NIH R01-CA058860 and the Lon V Smith Foundation grant LVS-39420; **UHN**: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; **UKO**: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre; **UKR**: Cancer Research UK (C490/A6187), UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; **USC**: R01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2H0200); **VAN**: BC Cancer Foundation, VGH & UBC Hospital Foundation; **VTL**: NIH K05-CA154337; **WMH**: National Health and Medical Research Council of Australia, Enabling Grants 310670 and 628903.

Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16; **WOC**: National Science Centren (N N301 5645 40) The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of the Ovarian Cancer Association Consortium through their donations to the Ovarian Cancer Research Fund. The OncoArray and COGS genotyping projects would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Marjorie J. Riggan (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility. We pay special tribute to the contribution of Professor Brian Henderson to the GAME-ON consortium and to Olga M. Sinilnikova for her contribution to CIMBA and for her part in the initiation and coordination of GEMO until she sadly passed away on the 30th June 2014. We thank the study participants, doctors, nurses, clinical and scientific collaborators, health care providers and health information sources who have contributed to the many studies contributing to this manuscript.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 30, 2018; revised October 16, 2018; accepted December 6, 2018; published first December 17, 2018.

References

- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin* 2018;68:284–96.
- Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. *Lancet* 2014;384:1376–88.
- Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 2017;49:680.
- Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development, progression, and therapy: an epigenetic overview. *Int J Mol Sci* 2013;14:21087–113.
- Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. *Carcinogenesis* 2010;31:27–36.
- Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. *Genome Biol* 2011;12:R10.
- Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. *Cancer Res* 2016;76:3446–50.
- Earp MA, Cunningham JM. DNA methylation changes in epithelial ovarian cancer histotypes. *Genomics* 2015;106:311–21.
- Koukoura O, Spandidos DA, Daponte A, Sifakis S. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy. *Mol Med Rep* 2014;10:3–9.
- Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo U-S. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. *Cancer Res* 2002;62:4151–6.
- Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, et al. DNA hypomethylation and ovarian cancer biology. *Cancer Res* 2004;64:4472–80.
- Koestler DC, Chalise P, Cicek MS, Cunningham JM, Armasu S, Larson MC, et al. Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. *BMC Med Genet* 2014;7:8.
- Fridley BL, Armasu SM, Cicek MS, Larson MC, Wang C, Winham SJ, et al. Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. *BMC Med Genet* 2014;7:21.
- Winham SJ, Armasu SM, Cicek MS, Larson MC, Cunningham JM, Kalli KR, et al. Genomewide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. *Genet Epidemiol* 2014;38:457–66.
- Wu D, Yang H, Winham SJ, Natanzon Y, Koestler DC, Luo T, et al. Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. *J Hum Genet* 2018;63:339–48.
- Grundberg E, Meduri E, Sandling JK, Hedman ÅK, Keildson S, Buil A, et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. *Am J Hum Genet* 2013;93:876–90.
- McRae AF, Powell JE, Henders AK, Bowdler L, Hemani G, Shah S, et al. Contribution of genetic variation to transgenerational inheritance of DNA methylation. *Genome Biol* 2014;15:R73.
- Gaunt TR, Shihab HA, Hemani G, Min JL, Woodward G, Lyttleton O, et al. Systematic identification of genetic influences on methylation across the human life course. *Genome Biol* 2016;17:61.
- McRae A, Marioni RE, Shah S, Yang J, Powell JE, Harris SE, et al. Identification of 55,000 replicated DNA methylation QTL. *Sci Rep* 2018;8:17605. doi: 10.1038/s41598-018-35871-w.
- Richardson TG, Zheng J, Smith GD, Timpson NJ, Gaunt TR, Relton CL, et al. Mendelian randomization analysis identifies CpG sites as putative mediators for genetic influences on cardiovascular disease risk. *Am J Hum Genet* 2017;101:590–602.
- Richardson TG, Haycock PC, Zheng J, Timpson NJ, Gaunt TR, Davey Smith G, et al. Systematic Mendelian randomization framework elucidates hundreds of CpG sites which may mediate the influence of genetic variants on disease. *Hum Mol Genet* 2018;27:3293–304.

22. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. *Am J Epidemiol* 1979;110:281–90.
23. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 2014;30:1363–9.
24. Friedman J, Hastie T, Tibshirani R. glmnet: lasso and elastic-net regularized generalized linear models. R package version 2009;1. Available from: <https://cran.r-project.org/web/packages/glmnet/glmnet.pdf>.
25. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001;29:308–11.
26. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun* 2018;9:1825.
27. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet* 2018;50:968–78.
28. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018;562:203–9.
29. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 2012;44:369.
30. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38:e164.
31. Lin H, Yin X, Xie Z, Lunetta KL, Lubitz SA, Larson MG, et al. Methylome-wide association study of atrial fibrillation in Framingham Heart Study. *Sci Rep* 2017;7:40377.
32. da Cunha Colombo Bonadio RR, Fogage RN, Miranda VC, Diz MdPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. *Clinics* 2018;73:e450s.
33. Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. *Gynecol Oncol Res Pract* 2017;4:4.
34. Consortium G. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 2015;348:648–60.
35. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 2012;44:369–75.
36. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 2010;42:874.
37. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21. *Nat Commun* 2013;4:1627.
38. Stricker R, Reiser G. Functions of the neuron-specific protein ADAP1 (centaurin- α 1) in neuronal differentiation and neurodegenerative diseases, with an overview of structural and biochemical properties of ADAP1. *Biol Chem* 2014;395:1321–40.
39. Galvita A, Grachev D, Azarashvili T, Baburina Y, Krestinina O, Stricker R, et al. The brainspecific protein, p42IP4 (ADAP 1) is localized in mitochondria and involved in regulation of mitochondrial Ca²⁺. *J Neurochem* 2009;109:1701–13.
40. Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF. Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells. *Mol Cancer Res* 2014;12:1140–5.
41. Borroni B, Agosti C, Magnani E, Di Luca M, Padovani A. Genetic bases of progressive supranuclear palsy: the MAPT tau disease. *Curr Med Chem* 2011;18:2655–60.
42. Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. *Mol Psychiatry* 2015;20:1588–95.
43. Wang K, Mullersman J, Liu X. Family-based association analysis of the MAPT gene in Parkinson. *J Appl Genet* 2010;51:509–14.
44. Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, et al. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. *Breast Cancer Res* 2010;12:R43.
45. Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, et al. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. *Cancer Chemother Pharmacol* 2013;71:1159–71.
46. Yamashita T, Tazawa S, Yawei Z, Katayama H, Kato Y, Nishiwaki K, et al. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. *Int J Oncol* 2006;28:931–8.
47. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun* 2016;7:12675.
48. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, et al. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. *Cancer Epidemiol Biomarkers Prev* 2015;24:1574–84.
49. Lord CC, Thomas G, Brown JM. Mammalian alpha beta hydrolase domain (ABHD) proteins: lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. *Biochim Biophys Acta* 2013;1831:792–802.
50. Katoh Y, Katoh M. Identification and characterization of ARHGAP27 gene *in silico*. *Int J Mol Med* 2004;14:943–7.
51. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, et al. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. *Cancer Res* 2018;78:5419–30.
52. Stueve TR, Li W-Q, Shi J, Marconett CN, Zhang T, Yang C, et al. Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. *Hum Mol Genet* 2017;26:3014–27.
53. Hannon E, Weedon M, Bray N, O'Donovan M, Mill J. Pleiotropic effects of trait-associated genetic variation on DNA methylation: utility for refining GWAS loci. *Am J Hum Genet* 2017;100:954–9.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Yaohua Yang, Lang Wu, Xiang Shu, et al.

Cancer Res 2019;79:505-517. Published OnlineFirst February 1, 2019.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-18-2726](https://doi.org/10.1158/0008-5472.CAN-18-2726)

Supplementary Material Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2018/12/15/0008-5472.CAN-18-2726.DC1>

Cited articles This article cites 52 articles, 7 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/79/3/505.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/79/3/505>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.